Home

Federal Government Relations

Therapeutic Discovery Project Defending America's Competitiveness in Biotechnology

Capital formation challenges in the industry have forced many biotech companies to halt projects, lay off staff or shutdown all together. Our analysis shows that the industry is approximately one-quarter smaller than it was in 2008.

Therapeutic Discovery Project Helps Scientists Working To Cure Cancer

BIO believes that the level of support provided by the TDP simply cannot meet the needs of the growing biotech field. As evidence of the project's popularity suggests, Congress should consider extending or expanding the project in order to support American innovation and speed the development of life-saving cures.

Therapeutic Discovery Project Is Working to Create & Protect American Jobs

The biotech industry is a thriving sector employing 1.3 million Americans in high quality, high paying jobs.

Developing Policies that Foster Innovation

Acorda Therapeutics' Ron Cohen presented testimony on the importance of federal policies to support the biotechnology industry at a House Committee on Science, Space and Technology, Subcommittee on Technology and Innovation hearing on March 27, a summary of his testimony is presented here

The JOBS Act: Critical Support for Today’s Emerging Biotech Company

The House and Senate passed H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act. It is now headed to the White House for President Obama’s signature.

OncoMed Pharmaceuticals SVP/CFO on Emerging Company Capital Formation Testimony

William D. Waddill, Senior Vice President and Chief Financial Officer of OncoMed Pharmaceuticals, highlights the importance of capital formation to encourage investment in the biotechnology industry and spur job growth. Mr. Waddill provided testimony today on behalf of BIO at a Senate Committee on Banking, Housing, and Urban Affairs hearing.

BIO Media Briefing Highlights 2012 Policy Priorities

BIO President & CEO Jim Greenwood and Tom Watkins, President & CEO of Human Genome Sciences and Chair of BIO’s Board of Directors, recently hosted a media briefing to recap our advocacy accomplishments in 2011 and lay out BIO’s policy priorities for 2012.

Podcast: BIO Media Briefing Highlights 2012 Policy Priorities

BIO President & CEO Jim Greenwood and Tom Watkins, President & CEO of Human Genome Sciences and Chair of BIO’s Board of Directors, recently hosted a media briefing to recap our advocacy accomplishments in 2011 and lay out BIO’s policy priorities for 2012.

BIO's 2012 Legislative Priorities - Part II

BIOtech-NOW's Tracy Cooley discusses the legislative year ahead with Brent Del Monte, BIO's Vice President of Federal Government Relations.

2011: A Pivotal Year for Biotechnology

Biotechnology continues to hold the greatest promise to address many of the most critical issues facing our world.

BIO's 2012 Legislative Priorities

BIOtech-NOW's Tracy Cooley discusses the legislative year ahead with Brent Del Monte, BIO's Vice President of Federal Government Relations. In this two part series, Del Monte discusses the outlook for 2012 and legislative priorities.

Therapeutic Discovery Project: 7 Companies, 1 Year Later

The Therapeutic Discovery Project provided much-needed relief for emerging biotech companies  working on life-saving treatments and cures

Capital Conundrum

The biotech industry has shrunk dramatically in recent years based primarily on the continued tight capital markets and increased aversion to risk on the part of investors.

Focus on Jobs from Biofuels and Biobased Products

On July 26, Agriculture Secretary Tom Vilsack announced four new project areas for the Biomass Crop Assistance Program.

The Value Proposition for Cellulosic and Advanced Biofuels Under the Federal Renewable Fuel Standard

Letters, Testimony & Comments

BIO's Testimony to the House Appropriations, Labor HHS Subcommittee on the President's FY 2013 Budget Request for the National Institutes of Health (NIH)
March 20 2012
Good morning Chairman Rehberg, Ranking Member DeLauro, Members of the Committee, ladies, and gentlemen. I am Scott Koenig, President and...
BIO Supports the JOBS Act (H.R. 3606)
March 16 2012
Dear Majority Leader Reid and Minority Leader McConnell: On behalf of the Biotechnology Industry Organization (BIO) and its more than 1...
Spurring Job Growth Through Capital Formation While Protecting Investors
March 6 2012
William D. Waddill, Senior Vice President and Chief Financial Officer OncoMed Pharmaceuticals highlights the importance of capital...
BIO Written Testimony: Spurring Job Growth Through Capital Formation While Protecting Investors
December 1 2011
On December 1, BIO submitted written testimony to the Senate Committee on Banking, Housing, and Urban Affairs on the importance of...
Testimony in Support of USDA Research
July 28 2011
The Biotechnology Industry Organization (BIO) is the world's largest biotechnology organization, providing advocacy, business...
More Letters, Testimony & Comments →

Press Releases

BIO Submits Comments on FDA Draft Guidances on Biosimilars
April 17 2012
Washington, D.C. (April 17, 2012) – The Biotechnology Industry Organization (BIO) submitted comments yesterday...
BIO Applauds Congress for Passage of the Jumpstart Our Business Startups (JOBS) Act
March 27 2012
The Biotechnology Industry Organization (BIO) praises the House and Senate for passage of H.R. 3606, the Jumpstart...
Biotech Leader Provides Testimony at Congressional Hearing on ‘Spurring Job Growth through Capital Formation While Protecting Investors’
March 6 2012
Today, the Senate Committee on Banking, Housing, and Urban Affairs held a hearing on “Spurring Job Growth...
TREAT Act Offers Renewed Hope for Patients
February 15 2012
Washington, DC (February 15, 2012) – Today, the Biotechnology Industry Organization (BIO) praised Sen. Kay...
Biotechnology Can Provide Foundation for A U.S. Economy “Built To Last”
January 25 2012
BIO Calls On the Administration and Congress to Embrace Proposals to Unleash the Promise of Biotechnology...
More Press Releases →